BCL2 and glioblastoma: Recently, literature has reported higher expressions of XIAP and Bcl-2 in the GBM samples than that of normal brain samples and XIAP involved in apoptosis resistance [45]; thus, XIAP has been recognized to be the best way to develop new target therapy strategies among GBM patients.